Literature DB >> 19172415

Characteristics, mechanisms of action, and epitope mapping of anti-factor VIII antibodies.

Géraldine Lavigne-Lissalde1, Chantal Rothschild, Claire Pouplard, Priscilla Lapalud, Yves Gruel, Jean-François Schved, Claude Granier.   

Abstract

The development of anti-factor VIII (FVIII) antibodies (Abs), also called inhibitors, is currently one of the most serious complications arising during the treatment of hemophilia A patients. Improved prevention and eradication of these Abs remain a challenge both for clinicians and scientists. Numerous studies in the literature have reported on their epitope specificity, on their mechanism of FVIII inactivation, as well as on the methods used for their detection. In this review, we summarize the current knowledge on the nature (isotypes, kinetic properties), epitope properties, and mechanisms of action of anti-FVIII Abs. Furthermore, we present methods for detection and epitope characterization of anti-FVIII Abs with emphasis on the Luminex technique susceptible to facilitate the monitoring of changes in the epitope specificity of these Abs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19172415     DOI: 10.1007/s12016-009-8119-0

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  76 in total

1.  Analysis of the North American Immune Tolerance Registry (NAITR) 1993-1997: current practice implications. ISTH Factor VIII/IX Subcommittee Members.

Authors:  D M DiMichele; B L Kroner
Journal:  Vox Sang       Date:  1999       Impact factor: 2.144

Review 2.  Acquired coagulation inhibitor-associated bleeding disorders: an update.

Authors:  Massimo Franchini; Dino Veneri
Journal:  Hematology       Date:  2005-12       Impact factor: 2.269

3.  Prediction of inhibitors in hemophilia.

Authors:  G C White
Journal:  J Thromb Haemost       Date:  2008-10-28       Impact factor: 5.824

4.  Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation.

Authors:  C R Hay; C A Ludlam; B T Colvin; F G Hill; F E Preston; N Wasseem; R Bagnall; I R Peake; E Berntorp; E P Mauser Bunschoten; K Fijnvandraat; C K Kasper; G White; E Santagostino
Journal:  Thromb Haemost       Date:  1998-04       Impact factor: 5.249

5.  Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII.

Authors:  P C Spiegel; M Jacquemin; J M Saint-Remy; B L Stoddard; K P Pratt
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

6.  The humoral response to human factor VIII in hemophilia A mice.

Authors:  J F Healey; E T Parker; R T Barrow; T J Langley; W R Church; P Lollar
Journal:  J Thromb Haemost       Date:  2006-12-20       Impact factor: 5.824

7.  Low molecular weight peptides restore the procoagulant activity of factor VIII in the presence of the potent inhibitor antibody ESH8.

Authors:  Sylvie Villard; Dominique Piquer; Sanjee Raut; Jean-Paul Léonetti; Jean-Marie Saint-Remy; Claude Granier
Journal:  J Biol Chem       Date:  2002-05-14       Impact factor: 5.157

8.  Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction.

Authors:  J G Gilles; J Arnout; J Vermylen; J M Saint-Remy
Journal:  Blood       Date:  1993-10-15       Impact factor: 22.113

9.  The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX.

Authors:  P J Lenting; J W van de Loo; M J Donath; J A van Mourik; K Mertens
Journal:  J Biol Chem       Date:  1996-01-26       Impact factor: 5.157

10.  A role for the C2 domain of factor VIII in binding to von Willebrand factor.

Authors:  E L Saenko; M Shima; K J Rajalakshmi; D Scandella
Journal:  J Biol Chem       Date:  1994-04-15       Impact factor: 5.157

View more
  4 in total

1.  Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.

Authors:  Y Dargaud; A Pavlova; S Lacroix-Desmazes; K Fischer; M Soucie; S Claeyssens; D W Scott; R d'Oiron; G Lavigne-Lissalde; G Kenet; C Escuriola Ettingshausen; A Borel-Derlon; T Lambert; G Pasta; C Négrier
Journal:  Haemophilia       Date:  2016-01       Impact factor: 4.287

2.  Characterization of anti-factor VIII antibody in a patient with acquired hemophilia A.

Authors:  Jisu Oh; Yeongmin Lim; Moon Ju Jang; Ji Young Huh; Midori Shima; Doyeun Oh
Journal:  Blood Res       Date:  2013-03-25

3.  Rhesus monkeys and baboons develop clotting factor VIII inhibitors in response to porcine endothelial cells or islets.

Authors:  John M Stewart; Alice F Tarantal; Wayne J Hawthorne; Evelyn J Salvaris; Philip J O'Connell; Mark B Nottle; Anthony J F d'Apice; Peter J Cowan; Mary Kearns-Jonker
Journal:  Xenotransplantation       Date:  2014-05-08       Impact factor: 3.907

Review 4.  Tolerating Factor VIII: Recent Progress.

Authors:  Sebastien Lacroix-Desmazes; Jan Voorberg; David Lillicrap; David W Scott; Kathleen P Pratt
Journal:  Front Immunol       Date:  2020-01-10       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.